Skip to content

EBIT at other companies

Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$128.51M+32.8%
Absci Corporation logo
Absci CorporationABSI
-$30.85M-11.2%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$57.52M+8.2%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.59M+7.4%
Certara, Inc. logo
Certara, Inc.CERT
-$4.3M-156%
Cadence Design Systems logo
Cadence Design SystemsCDNS

Other financials

Income statement

See full
Revenue$58.6M-1.6%
Gross profit$29.5M-5.1%
Operating income-$48.8M+4.1%
Net income-$60.0M-0.4%
EPS (diluted)-$0.81+1.2%

Balance sheet

See full
Cash & equivalents$267.7M-20.7%
Total debt$107.0M-7.9%
Total equity$313.5M-16.1%
Total assets$634.2M-14.6%

Cash flow

See full
Operating cash flow-$14.8M-110%
CapEx$2.5M+321%
Free cash flow-$17.3M-112%

Valuation

See full
Market cap$1.15B-23.7%
Enterprise value$984.71M-23.1%
P/S4.5×-2.0×

Profitability

See full
Gross margin55.3%-7.3pp
Operating margin-64.7%-12.0pp
Net margin-68.5%
FCF margin9.6%+5.1pp

Returns & leverage

See full
Return on equity-45.7%
Debt / equity0.3×0.0×
Current ratio2.7×-0.7×

Where this comes from

Calculated from Schrodinger’s reported figures.

Plus components not separately reported this period.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schrodinger's EBIT?
Schrodinger (SDGR) reported EBIT of -$48.79M in Q1 2026.
How has Schrodinger's EBIT changed year-over-year?
Schrodinger's EBIT increased by 4.1% year-over-year, from -$50.89M to -$48.79M.
What is the long-term trend for Schrodinger's EBIT?
Over 4 years (2021 to 2025), Schrodinger's EBIT has grown at a 10.6% compound annual growth rate (CAGR), from -$111.44M to -$166.9M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.